Hepion Pharmaceuticals
- Country
- πΊπΈUnited States
- Ownership
- Public
- Employees
- 22
- Market Cap
- $4.5M
- Website
- http://www.hepionpharma.com
- Introduction
Hepion Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of drug therapy for treatment of chronic liver diseases. It focuses on the development of its product candidate rencofilstat, a cyclophilin inhibitor that targets biochemical pathways involved in the progression of liver disease. The company was founded on May 15, 2013 and is headquartered in Edison, NJ.
Single Dose ADME Study of [14C]-Rencofilstat in Healthy Male Subjects
- Conditions
- NASH With Fibrosis
- Interventions
- Drug: [14C]-rencofilstat 225mg
- First Posted Date
- 2023-02-21
- Last Posted Date
- 2024-10-03
- Lead Sponsor
- Hepion Pharmaceuticals, Inc.
- Target Recruit Count
- 6
- Registration Number
- NCT05737433
- Locations
- π¬π§
Quotient Sciences, Nottingham, United Kingdom
A Study to Evaluate the Safety and Efficacy of Rencofilstat in Adult Subjects With NASH F3
- Conditions
- NASH With Fibrosis
- Interventions
- Drug: rencofilstat, 75 mgDrug: rencofilstat, 150mgDrug: rencofilstat, 225 mg
- First Posted Date
- 2022-07-15
- Last Posted Date
- 2024-06-13
- Lead Sponsor
- Hepion Pharmaceuticals, Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT05461105
- Locations
- πΊπΈ
Arizona Liver Health-Tucson, Tucson, Arizona, United States
πΊπΈSynergy Healthcare, LLC, Bradenton, Florida, United States
πΊπΈCovenant Metabolic Specialists-Fort Myers, Fort Myers, Florida, United States
A Study to Evaluate the Efficacy and Safety of Rencofilstat in Subjects With NASH and Advanced Liver Fibrosis
- Conditions
- Nonalcoholic Steatohepatitis (NASH)NAFLDFibrosis, Liver
- Interventions
- Drug: Placebo
- First Posted Date
- 2022-06-02
- Last Posted Date
- 2024-05-03
- Lead Sponsor
- Hepion Pharmaceuticals, Inc.
- Target Recruit Count
- 120
- Registration Number
- NCT05402371
- Locations
- πΊπΈ
Entrust Clinical Research, Miami, Florida, United States
πΊπΈUnited Reseach Group, Miami, Florida, United States
πΊπΈSynergy Healthcare, LLC, Bradenton, Florida, United States
A Study of CRV431 Dosed Once Daily in NASH Induced F2 and F3 Subjects
- Conditions
- Fibrosis, LiverNAFLD - Nonalcoholic Fatty Liver DiseaseNASH - Nonalcoholic Steatohepatitis
- Interventions
- Drug: Placebo (3 softgels)Drug: CRV431 75mgDrug: Placebo (1 softgel)Drug: CRV431 225mg
- First Posted Date
- 2020-07-21
- Last Posted Date
- 2022-07-15
- Lead Sponsor
- Hepion Pharmaceuticals, Inc.
- Target Recruit Count
- 47
- Registration Number
- NCT04480710
- Locations
- πΊπΈ
La Salud Research, Inc., Miami, Florida, United States
πΊπΈGastrointestinal Specialists of Georgia, Marietta, Georgia, United States
πΊπΈConquest Clinical Research, Orange, California, United States
A Study in Healthy Volunteers
- Conditions
- Liver DiseasesHepatitis BInfectious Disease
- Interventions
- First Posted Date
- 2018-07-24
- Last Posted Date
- 2021-12-01
- Lead Sponsor
- Hepion Pharmaceuticals, Inc.
- Target Recruit Count
- 92
- Registration Number
- NCT03596697
- Locations
- πΊπΈ
Pinnacle Clinical Research, San Antonio, Texas, United States
πΊπΈCelerion, Inc, Lincoln, Nebraska, United States